Genome&Company cuts convertible bond conversion price to KRW 5,240 from KRW 6,420
Genome&Company reset the conversion price on its unlisted 4th convertible bond to KRW 5,240 from KRW 6,420. Move increases shares issuable on conversion to 5,152,671 from 4,205,607 against KRW 27 billion outstanding principal. Reset takes effect Oct. 13, 2026, reflecting a market-price adjustment mechanism. Disclaimer